BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
화요일, 9월 22

Quince Therapeutics Inc

QNCXNASDAQ
Trade with Public
Trade with Public
$31.35
0.351.13%
가까이에: Sep 22, 5:00 PM EST
$27.92
-3.43-10.94%
시간외: Sep 14, 7:40 AM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Quince Therapeutics Financials

Quince Therapeutics (QNCX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Quince Therapeutics Q2 EPS $(12.31) Beats $(26.32) Estimate

Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(12.31) per share which beat the analyst consensus estimate of $(26.32) by 53.21 percent. This is a 81.9 percent increase over losses of $(68.00) per share
Benzinga Newsdesk

Gold Moves Lower; CVS Health Earnings Top Views

Avi Kapoor

PRO
Quince Therapeutics Q3 EPS $(0.25) Misses $(0.21) Estimate

Benzinga Newsdesk

PRO
Quince Therapeutics Q2 EPS $(0.34) Misses $(0.26) Estimate

Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.26) by 30.77 percent. This is a 46.88 percent increase over losses of $(0.64) per share
Benzinga Newsdesk

PRO
Quince Therapeutics Q3 EPS $(0.13) Up From $(0.15) YoY

Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(0.13) per share. This is a 13.33 percent increase over losses of $(0.15) per share from the same period last year.
Benzinga Newsdesk

PRO
Quince Therapeutics Q2 EPS $(0.64) Down From $(0.14) YoY

Quince Therapeutics (NASDAQ: QNCX) reported quarterly losses of $(0.64) per share. This is a 357.14 percent decrease over losses of $(0.14) per share from the same period last year.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved